Joe Baby, continue to keep your eyes peeled to these kinds of speaking opportunities for the Hirschmeister. Having him talk to captive audiences who are interested in furthering the research and development of AIDS therapies is how we'll start to gain visibility and begin to position Advanced Viral as a leader in innovative medical research.
The meeeting you pointed out however is not where I would point him. In fact, if someone asked me ahead of time, I would not have put him at the AAAS meeting in Washington where he spoke either. He needs to present abstracts on the science of Reticulose at meetings such as the Infectious Diseases Society of America (IDSA), Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), International Congress of Chemotherapy (ICC), and definetly the Hambricht & Quist annual meeting. Let's not overlook BIO either.
Even if he doesn't present abstracts at these meetings, publicity support can be built around clinical data that is current when these meetings take place. For example, this year ICAAC takes place in Toronto. Approximately 25-30,000 people are expected to attend. These include not only the medical professionals you would expect, but also the pharmaceutical executives and stock analysts who are looking for novel therapies to underwrite. If the publication of this Barbados data (that Bregman already is announcing) will appear sometime around that meeting, then ADVR should bombard the town of Toronto with messages about this study DURING ICAAC. It's called local market media outreach. When executed correctly, it wins, big. More later.
Buy now. |
